Gain Therapeutics, Inc. (GANX)

Gain Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	13.08	20.84	10.39	11.79	7.31	36.88
Short-Term Investments	-	-	-	5	12.83	-
Cash & Short-Term Investments	13.08	20.84	10.39	16.79	20.14	36.88
Cash Growth	95.46%	100.64%	-38.16%	-16.61%	-45.40%	392.21%
Other Receivables	1.03	0.8	0.77	0.24	0.19	0.2
Receivables	1.03	0.8	0.77	0.24	0.19	0.2
Prepaid Expenses	0.85	0.6	0.45	0.74	0.76	0.65
Total Current Assets	14.97	22.24	11.6	17.78	21.09	37.72
Property, Plant & Equipment	0.31	0.41	0.32	0.59	0.8	1.01
Long-Term Investments	-	-	-	-	1.94	-
Other Intangible Assets	0.08	0.1	0.13	0.19	0.21	0.2
Other Long-Term Assets	0.06	0.07	0.06	0.05	0.05	0.05
Total Assets	15.42	22.82	12.12	18.61	24.1	38.99

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	1.22	0.83	0.95	1.32	1.63	0.56
Accrued Expenses	1.91	2.26	2.42	2.11	2	1.4
Current Portion of Long-Term Debt	0.12	0.1	0.11	0.12	0.11	0.1
Current Portion of Leases	0.11	0.12	0.16	0.23	0.23	0.22
Current Income Taxes Payable	0.07	0.04	0.02	0.05	0.11	0
Current Unearned Revenue	-	-	0.25	1.12	0.06	0.27
Total Current Liabilities	3.43	3.35	3.91	4.95	4.13	2.55
Long-Term Debt	0.22	0.3	0.33	0.45	0.5	0.59
Long-Term Leases	0.16	0.21	0.05	0.23	0.44	0.7
Long-Term Unearned Revenue	-	-	0.05	0.09	-	-
Pension & Post-Retirement Benefits	0.32	0.39	0.44	0.31	0.16	0.33
Total Liabilities	4.13	4.25	4.78	6.03	5.22	4.17

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	0	0	0	0	0	0
Additional Paid-In Capital	121.92	119.14	88.78	73.11	57.36	55.83
Retained Earnings	-111.64	-101.36	-81.19	-60.78	-38.52	-20.93
Comprehensive Income & Other	1	0.78	-0.25	0.25	0.04	-0.09
Total Common Equity	11.29	18.56	7.34	12.58	18.88	34.82
Shareholders' Equity	11.29	18.56	7.34	12.58	18.88	34.82
Total Liabilities & Equity	15.42	22.82	12.12	18.61	24.1	38.99

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	0.61	0.73	0.65	1.03	1.27	1.61
Net Cash (Debt)	12.47	20.11	9.73	15.77	20.81	35.27
Net Cash Growth	107.44%	106.57%	-38.27%	-24.22%	-41.01%	466.03%
Net Cash Per Share	0.32	0.61	0.43	1.21	1.75	3.47
Filing Date Shares Outstanding	43.64	42.24	27.79	16.22	11.88	11.88
Total Common Shares Outstanding	43.34	42.07	27.13	16.21	11.88	11.88
Working Capital	11.54	18.88	7.69	12.83	16.97	35.17
Book Value Per Share	0.26	0.44	0.27	0.78	1.59	2.93
Tangible Book Value	11.22	18.46	7.21	12.38	18.67	34.61
Tangible Book Value Per Share	0.26	0.44	0.27	0.76	1.57	2.91
Machinery	0.18	0.22	0.2	0.18	0.17	0.12
Leasehold Improvements	0.04	0.04	0.03	0.03	0.03	0.02

SEC Filings: 10-K · 10-Q

Data Source: S&P Global Market Intelligence Last updated: May 11, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 26, 2026

Data Sources Report a data error